Story perspectives

FDA Official Critiques UniQure's Huntington's Treatment Amid Tensions

3/7/2026

Summary

Story summary

An anonymous senior FDA official criticized UniQure's experimental Huntington's disease treatment during an FDA media call, according to Adam Feuerstein.
During the call, Bloomberg reporter Robert Langreth questioned the official's tenure at FDA.
The official said he longs for roles as professor and doctor but will stay at FDA if it serves the American people.
The exchange highlights tensions within the FDA over drug development and public health priorities.

History

Historical Context

The 1962 Kefauver-Harris Amendments, enacted after the thalidomide tragedy that caused thousands of birth defects, mandated rigorous drug testing for efficacy and safety, reshaping FDA regulations. This historical context highlights ongoing tensions within the FDA, as officials express concerns over balancing innovation with public health, particularly regarding experimental treatments like UniQure's for Huntington's disease, impacting future drug approvals.

1 of 2

Story summary

An anonymous senior FDA official criticized UniQure's experimental Huntington's disease treatment during an FDA media call, according to Adam Feuerstein.
During the call, Bloomberg reporter Robert Langreth questioned the official's tenure at FDA.
The official said he longs for roles as professor and doctor but will stay at FDA if it serves the American people.
The exchange highlights tensions within the FDA over drug development and public health priorities.

1 / 2